GENSCRIPT BIO's stock price plummeted 5.54% during intraday trading on Thursday, marking a significant reversal from its previous session's gains.
The decline appears to be driven by profit-taking activity following a rally in the prior session, which was catalyzed by positive research results from its associate company Legend Biotech at the ASCO annual meeting. Additionally, concerns over institutional selling have emerged, with Hong Kong Stock Connect channels experiencing consecutive days of significant net outflows prior to this session.
Broad weakness across the Life Sciences Tools & Services sector further pressured sentiment, with multiple major players in the space also trading lower during the session, contributing to the overall downward movement in GENSCRIPT BIO's share price.
Comments